Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.
Nelfinavir is a potent HIV-protease inhibitor with pleiotropic effects in cancer cells. Experimental studies connect its anti-cancer effects to the suppression of the Akt signaling pathway, but the actual molecular targets remain unknown. Using a structural proteome-wide off-target pipeline, which i...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-04-01
|
Series: | PLoS Computational Biology |
Online Access: | http://europepmc.org/articles/PMC3084228?pdf=render |
id |
doaj-5b1e198a6da4490097d5b923716ba8b5 |
---|---|
record_format |
Article |
spelling |
doaj-5b1e198a6da4490097d5b923716ba8b52020-11-24T21:56:05ZengPublic Library of Science (PLoS)PLoS Computational Biology1553-734X1553-73582011-04-0174e100203710.1371/journal.pcbi.1002037Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.Li XieThomas EvangelidisLei XiePhilip E BourneNelfinavir is a potent HIV-protease inhibitor with pleiotropic effects in cancer cells. Experimental studies connect its anti-cancer effects to the suppression of the Akt signaling pathway, but the actual molecular targets remain unknown. Using a structural proteome-wide off-target pipeline, which integrates molecular dynamics simulation and MM/GBSA free energy calculations with ligand binding site comparison and biological network analysis, we identified putative human off-targets of Nelfinavir and analyzed the impact on the associated biological processes. Our results suggest that Nelfinavir is able to inhibit multiple members of the protein kinase-like superfamily, which are involved in the regulation of cellular processes vital for carcinogenesis and metastasis. The computational predictions are supported by kinase activity assays and are consistent with existing experimental and clinical evidence. This finding provides a molecular basis to explain the broad-spectrum anti-cancer effect of Nelfinavir and presents opportunities to optimize the drug as a targeted polypharmacology agent.http://europepmc.org/articles/PMC3084228?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Li Xie Thomas Evangelidis Lei Xie Philip E Bourne |
spellingShingle |
Li Xie Thomas Evangelidis Lei Xie Philip E Bourne Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS Computational Biology |
author_facet |
Li Xie Thomas Evangelidis Lei Xie Philip E Bourne |
author_sort |
Li Xie |
title |
Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. |
title_short |
Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. |
title_full |
Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. |
title_fullStr |
Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. |
title_full_unstemmed |
Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. |
title_sort |
drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS Computational Biology |
issn |
1553-734X 1553-7358 |
publishDate |
2011-04-01 |
description |
Nelfinavir is a potent HIV-protease inhibitor with pleiotropic effects in cancer cells. Experimental studies connect its anti-cancer effects to the suppression of the Akt signaling pathway, but the actual molecular targets remain unknown. Using a structural proteome-wide off-target pipeline, which integrates molecular dynamics simulation and MM/GBSA free energy calculations with ligand binding site comparison and biological network analysis, we identified putative human off-targets of Nelfinavir and analyzed the impact on the associated biological processes. Our results suggest that Nelfinavir is able to inhibit multiple members of the protein kinase-like superfamily, which are involved in the regulation of cellular processes vital for carcinogenesis and metastasis. The computational predictions are supported by kinase activity assays and are consistent with existing experimental and clinical evidence. This finding provides a molecular basis to explain the broad-spectrum anti-cancer effect of Nelfinavir and presents opportunities to optimize the drug as a targeted polypharmacology agent. |
url |
http://europepmc.org/articles/PMC3084228?pdf=render |
work_keys_str_mv |
AT lixie drugdiscoveryusingchemicalsystemsbiologyweakinhibitionofmultiplekinasesmaycontributetotheanticancereffectofnelfinavir AT thomasevangelidis drugdiscoveryusingchemicalsystemsbiologyweakinhibitionofmultiplekinasesmaycontributetotheanticancereffectofnelfinavir AT leixie drugdiscoveryusingchemicalsystemsbiologyweakinhibitionofmultiplekinasesmaycontributetotheanticancereffectofnelfinavir AT philipebourne drugdiscoveryusingchemicalsystemsbiologyweakinhibitionofmultiplekinasesmaycontributetotheanticancereffectofnelfinavir |
_version_ |
1725859647036850176 |